956580-04-4

Basic information

• Product Name: methyl 140-Cyclohexyl-2,2-dimethylspiro[1,3-dioxane-5,70-indolo[1,2-e][1,5]benzoxazocine]-11-carboxylate
• Synonyms: methyl 140-Cyclohexyl-2,2-dimethylspiro[1,3-dioxane-5,70-indolo[1,2-e][1,5]benzoxazocine]-11-carboxylate
• CAS NO: 956580-04-4
• Molecular Weight: 489.612
• Mol File: 956580-04-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 140-Cyclohexyl-2,2-dimethylspiro[1,3-dioxane-5,70-indolo[1,2-e][1,5]benzoxazocine]-11-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 140-Cyclohexyl-2,2-dimethylspiro[1,3-dioxane-5,70-indolo[1,2-e][1,5]benzoxazocine]-11-carboxylate(956580-04-4)
• EPA Substance Registry System: methyl 140-Cyclohexyl-2,2-dimethylspiro[1,3-dioxane-5,70-indolo[1,2-e][1,5]benzoxazocine]-11-carboxylate(956580-04-4)

Safety Data

• Hazardous Substances Data: 956580-04-4(Hazardous Substances Data)

Upstream product

• 43153-20-4 5,5-bis-bromomethyl-2,2-dimethyl-[1,3]dioxane 
• 863578-50-1 3-cyclohexyl-2-(2-hydroxy-phenyl)-1H-indole-6-carboxylic acid methyl ester 
• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 89466-08-0 2-hydroxyphenyl boronic acid 

Downstream Products

• 956580-05-5 methyl 14-cyclohexyl-7,7-bis(hydroxymethyl)-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylate 
• 1260489-49-3 C₃₁H₃₉N₃O₃ 

Relevant articles and documents

Discovery of (7 R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6 H -indolo[1,2- e ][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase

Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral genome and has been a prime target for drug discovery eff

PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.